Diabetic foot infections and antibiotic therapy

Clinics in Podiatric Medicine and Surgery

Volumn 20, Issue 4, 2003, Pages 655-669

  Zgonis, Thomas ^a   Jolly, Gary Peter ^b   Buren, Benjamin J ^d   Blume, Peter ^c  

^a Ctr for Reconstructive Foot Surgery   (United States)

^b NEW BRITAIN GENERAL HOSPITAL   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; CALCIUM SULFATE; CEFADROXIL; CEFALEXIN; CEFAZOLIN; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLINAFLOXACIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DICLOXACILLIN; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; NAFCILLIN; OFLOXACIN; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL DISCOMFORT; ANAPHYLAXIS; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; BONE INFECTION; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DEBRIDEMENT; DIABETIC FOOT; DIABETIC FOOT INFECTION; DIAGNOSTIC IMAGING; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG PELLET; DRUG TISSUE LEVEL; ECHOGRAPHY; EMPIRIC THERAPY; ENTEROCOLITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFECTION; INSOMNIA; INTERSTITIAL NEPHRITIS; LABORATORY TEST; LIVER TOXICITY; MICROBIOLOGY; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; OTOTOXICITY; PRIORITY JOURNAL; QT PROLONGATION; RADIOGRAPHY; REVIEW; SCINTIGRAPHY; SOFT TISSUE INFECTION; TASTE DISORDER; TENDON RUPTURE; THROMBOCYTE DISORDER; THROMBOPHLEBITIS; VEIN DISEASE; VOMITING; XEROSTOMIA;

EID: 0242664969     PISSN: 08918422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-8422(03)00067-3     Document Type: Article

References (55)

1. Tan JS, Fiedman NM, Hazelton-Miller C, et al. Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputation? Clin Infect Dis 1996;23:286-91.
2. Grayson ML, Gibbons GW, Balogh K, et al. Probing to bone in infected pedal ulcers: a clinical sign of underlying osteomyelitis in diabetic patients. JAMA 1995;273:721-3.
3. Kaleta JL, Fleischli JW, Reilly CH. The diagnosis of osteomyelitis in diabetes using the erythrocyte sedimentation rate: a pilot study. J Am Podiatr Med Assoc 2001;91:445-50.
4. Lipsky BA, Pecoraro RE, Wheat JL. The diabetic foot: soft tissue and bone infection. Infect Dis Clin North Am 1990;4:409-32.
5. Pellizzer G, Strazzabosco M, Presi S, et al. Deep tissue biopsy vs. superficial swab culture monitoring in the microbiological assessment of limb-threatening diabetic foot infection. Diabet Med 2001;18:822-7.
6. Newman LG. Imaging techniques in the diabetic foot. Clin Podiatr Med Surg 1995;12:75-86.
7. Harvey J, Cohen MM. Technesium-99 labeled leukocytes in diagnosing diabetic osteomyelitis in the foot. J Foot Ankle Surg 1997;36:209-14.
8. Craig JG, Amin MB, Wu W, et al. Osteomyelitis of the diabetic foot: MR imaging-pathologic correlation. Radiology 1997;203:849-55.
9. Bonakdarpour A, Gaines VD. The radiology of osteomyelitis. Orthop Clin North Am 1983;14: 21-37.
10. Wheat J. Diagnostic strategies in osteomyelitis. Am J Med 1985;78:218-24.
11. Devillers A, Garin E, Polard JL, et al. Comparison of Tc-99m-labelled antileukocyte fragment Fab' and Tc-99m-HMPAO leukocyte scintigraphy in the diagnosis of bone and joint infections: a prospective study. Nucl Med Commun 2000;2:747-53.
12. Blume PA, Dey HM, Daley LJ, et al. Diagnosis of pedal osteomyelitis with Tec-99m HMPAO labeled leukocytes. J Foot Ankle Surg 1997;36:120-6.
13. Larcos G, Brown ML, Sutton RT. Diagnosis of osteomyelitis of the foot in diabetic patients: value of 111 In-leukocyte scintigraphy. AJR Am J Roentgenol 1991;157:527-31.
14. Cook TA, Rahim N, Sompson HCR, Gelland RB. Magnetic resonance imaging in the management of diabetic foot infection. Br J Surg 1996;83:245-8.
15. Lipman BT, Collier BD, Carrera GF, et al. Detection of osteomyelitis in the neuropathic foot: nuclear medicine, MRI and conventional radiology. Clin Nucl Med 1998;23:77-82.
16. Mason MD, Zlatkin MB, Esterhai JL, et al. Chronic complicated osteomyelitis of the lower extremity evaluation with MR imaging. Radiology 1989;173:355-9.
17. Ledermann HP, Morrision WB, Schweitzer ME, Raikin SM. Tendon involvement in pedal infection: MR analysis of frequency, distribution, and spread of infection. AJR Am J Roentgenol 2002;179:939-47.
18. Ledermann HP, Morrison WB, Schweitzer ME. Pedal abscesses in patients suspected of having pedal osteomyelitis: analysis with MR imaging. Radiology 2002;224:649-55.
19. Ledermann HP, Schweitzer ME, Morrison WB. Nonenhancing tissue on MR imaging of pedal infection: characterization of necrotic tissue and associated limitation for diagnosis of osteomyelitis and abscess. AJR Am J Roentgenol 2002;178:215-22.
20. Enderle MD, Coerper S, Schweizer HP, et al. Correlation of imaging techniques to histopathology in patients with diabetic foot syndrome and clinical suspecion of chronic osteomyelitis. The role of high-resolution ultrasound. Diabetes Care 1999;22:294-9.
21. O'Meara SM, Cullum NA, Majid M, Sheldon TA. Systemic review of antimicrobial agents used for chronic wounds. Br J Surg 2001;88:4-21.
22. Lipsky BA. Evidence-based antibiotic therapy of diabetic foot infections. FEMS Immunol Med Microbiol 1999;26:267-76.
23. Armstrong DG, Findlow AH, Oyibo SO, Boulton AJM. The use of absorbable antibiotic-impregnated calcium sulphate pellets in the management of diabetic foot infections. Diabet Med 2001; 11:942.
24. Nuermberger E, Auwaerter P. Johns Hopkins Division of Infectious Disease Antibiotic Guide. Baltimore (MD): Johns Hopkins University Division of Infectious Disease; 2002. Available at: abxfeedback@hopkins-abxguide.org.
25. Nix DE, Cumbo TJ, Kuritzsky P, et al. Oral ciprofloxacin in the treatment of serious soft tissue and bone infection: efficacy, safety, and pharmokinetics. Am J Med 1987;82:146-53.
26. Lipsky BA, Baker PD, Landon GC, Femau R. Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. Clin Infect Dis 1997;24:643-8.
27. Sesin GP, Paszko A, O'Keefe E. Oral clindamycin and ciprofloxacin therapy for diabetic foot infections. Pharmacotherapy 1990;10:154-6.
28. Goldstein EJ, Citron DM, Nesbit CA. Diabetic foot infections. Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases. Diabetes Care 1996;19: 638-41.
29. Siami G, Christou N, Eiseman I, Tack KJ. Clinafloxacin versus pipercillin-tazobactam in treatment of patients with severe skin and soft tissue infections. Antimicrob Agents Chemother 2001;45: 525-31.
30. Senneville E, Yazdanpanah Y, Cazaubiel M, et al. Rifampicin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis. J Antimicrob Chemother 2001;48:927-30.
31. Rissing JP. Antimicrobial therapy for chronic osteomyelitis in adults: role of the quinolones. Clin Infect Dis 1997;25:1327-33.
32. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996;40:839-45.
33. Miyasaki S, Fujikawa T, Kobayashi I, et al. The in vitro and in vivo antibacterial characterization of vancomycin and linezolid against vancomycin-susceptible and resistant enterococci. J Antimicrob Chemother 2002;50:971-4.
34. Rubinstein E, Cammarata SK, Oliphant TH, et al, and the Linezolid Nosocomial Pneumonia Study Group. Linezolid PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32:402-12.
35. Stevens DL, Herr D, Lampiris H, et al, and the Linezolid MRSA Study Group. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34:1481-90.
36. Tentolouris N, Jude EB, Smimof I, et al. Methicillin-resistant staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabet Med 1999;16:767-71.
37. Roghmann MC, Siddiqui A, Plaisance K, Standiford H. MRSA colonization and the risk of MRSA bacteraemia in hospitalized patients with chronic ulcers. J Hosp Infect 2001;47:98-103.
38. Dang CN, Prasad YDM, Boulton AJM, Jude EB. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med 2003;20:159-61.
39. Lautenbach E, LaRosa LA, Marr AM, et al. Changes in the prevalence of vancomycin-resistant enterococci in response to antimicrobial formulary interventions: impact of progressive restrictions on use of vancomycin and third-generation cephalosporins. Clin Infect Dis 2003;36:440-6.
40. Lipsky BA. Osteomyelitis of the foot in diabetic patients. Clin Infect Dis 1997;25:1318-26.
41. Venkatesan P, Lawn S, Macfarlane RM, et al. Conservative management of osteomyelitis in the feet of diabetic patients. Diabet Med 1997;14:487-90.
42. Klepser ME, Marangos MN, Zhu Z, et al. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa. Antimicrob Agents Chemother 1997;41:435-9.
43. Zeillemaker AM, Veldkamp KE, Van Kraaij MG, et al. Pipercillin/ tazobactam therapy for diabetic foot infection. Foot Ankle Int 1998;19:169-72.
44. File TM, Tan JS. Ticarcillin-clavulanate therapy for bacterial skin and soft tissue infections. Rev Infect Dis 1991;13:733-6.
45. Akova M, Ozcebe O, Gullu I, et al. Efficacy of sulbactam-ampicillin for the treatment of severe diabetic foot infections. J Chemother 1996;8:284-9.
46. Raymakers JT, Houben AJ, Heyden JJ, et al. The effect of diabetes and severe ischaemia on the penetration of ceftazidime into tissue of the limb. Diabet Med 2001;18:229-34.
47. Grayson ML, Gibbons GW, Habershaw GM, et al. Use of ampicillin/sulbactam versus imipenem/cilastin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1994;18:683-93.
48. Pathare NA, Sathe SR. Antibiotic combinations in polymicrobic diabetic foot infections. Indian J Med Sci 2001;12:655-62.
49. Diamantopoulos EJ, Haritos D, Yfandi G, et al. Management and outcome of severe diabetic foot infections. Exp Clin Endocrinol Diabetes 1998;106:346-52.
50. Seabrook GR, Edmiston CE, Schmitt DD, et al. Comparison of serum and tissue antibiotic levels in diabetes-related foot infections. Surgery 1991;110:671.
51. Nehler MR, Whitehill TA, Bowers SP, et al. Intermediate-term outcome of primary digit amputation in patients with diabetes mellitus who have forefoot sepsis requiring hospitalization and presumed adequate circulatory status. J Vasc Surg 1999;30:509-17.
52. Bamberger DM, Duas GP, Gerding DN. Osteomyelitis in the feet of diabetic patients: long-term results, prognostic factors, and the role of antimicrobial and surgical therapy. Am J Med 1987;83: 653-60.
53. Lipsky BA, Pecoraro RE, Larson SA, et al. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch Intern Med 1990;150:790-7.
54. Bertoni AG, Saydah S, Brancati FL. Diabetes and the risk of infection-related mortality in the US. Diabetes Care 2001;24:1044-9.
55. Eckmam MH, Greenfield S, Mackey WC, et al. Foot infections in diabetic patients: decision and cost-effectiveness analysis. JAMA 1995;273:712-20.